Marinus Pharmaceuticals | S-8:员工福利计划证券登记
Marinus Pharmaceuticals | 8-K:重大事件
Marinus Pharmaceuticals | 8-K:重大事件
Marinus Pharmaceuticals | 8-K:重大事件
Marinus Pharmaceuticals | 10-Q:季度报表
Marinus Pharmaceuticals | 8-K:Marinus Pharmicals提供最新业务并报告2024年第一季度财务业绩
Marinus Pharmaceuticals | SC 13G:超过5%持股股东披露文件-Citadel Securities LLC(0.4%),Citadel Securities Group LP(0.4%)等
Marinus Pharmaceuticals | SC 13G:超过5%持股股东披露文件-TANG CAPITAL PARTNERS, LP(8.2%),Tang Capital Management, LLC(8.2%)等
Marinus Pharmaceuticals | 8-K:Marinus Pharmicals提供第三阶段RAISE试验的最新情况,并公布了2024年第一季度的初步财务业绩
Marinus Pharmaceuticals | DEFA14A:其他
Marinus Pharmaceuticals | DEF 14A:股东委托书决议
Marinus Pharmaceuticals | 8-K:重大事件
Marinus Pharmaceuticals | 4:持股变动声明-高管 Braunstein Scott
Marinus Pharmaceuticals | 10-K:年度报表
Marinus Pharmaceuticals | 8-K:Marinus Pharmicals提供最新业务并报告2023年第四季度和全年财务业绩
Marinus Pharmaceuticals | 4:持股变动声明-高管 MANNING MARTHA E
Marinus Pharmaceuticals | 4:持股变动声明-高管 Shafer Christina
Marinus Pharmaceuticals | 4:持股变动声明-高管 Hulihan Joseph
Marinus Pharmaceuticals | 4:持股变动声明-高管 Pfanstiel Steven
Marinus Pharmaceuticals | 4:持股变动声明-高管 Braunstein Scott
暂无数据